Papers
More filters
Patent•
05 Jan 1984
TL;DR: A water-soluble covalent polysaccharide-antigen conjugate with a molecular size between 140,000 and 4,500,000 dalton and a nominal poly-saccharides/protein ratio between 0.25 and 2, capable of producing T-cell dependent antibody response to poly-sarccharide from a number of pathogenic bacterial organisms is prepared by mixing Tcell dependent antigen with an electrophilically activated poly-Sarcide hapten which poly-charide had previously been heat sized until more than 60% attained
Abstract: A water-soluble covalent polysaccharide-antigen conjugate having a molecular size between 140,000 and 4,500,000 dalton and a nominal polysaccharide/protein ratio between 0.25 and 2, capable of producing T-cell dependent antibody response to polysaccharide from a number of pathogenic bacterial organisms is prepared by mixing T-cell dependent antigen with an electrophilically activated polysaccharide hapten which polysaccharide had previously been heat sized until more than 60% attained a molecular size between 200,000 and 2,000,000 dalton.
63 citations
Cited by
More filters
Patent•
30 Jul 1992TL;DR: In this paper, an improved method for producing oligosaccharide conjugate vaccines was proposed, which elicited a monospecific and homogeneous immune response to capsular polysaccharide.
Abstract: The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide. A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.
156 citations
Patent•
02 Jul 1986
TL;DR: Glycoproteinic conjugates having trivalent immunogenic activity obtained by binding, by a covalent bond, to a protein selected among CRM 197, tetanus toxoid, and pertussis toxin, wherein said oligosaccharidic haptens are previously activated by introducing terminal esters as mentioned in this paper.
Abstract: Glycoproteinic conjugates having trivalent immunogenic activity obtained by binding, by a covalent bond, to a protein selected among CRM 197, tetanus toxoid, and pertussis toxin, at least an oligosaccharidic hapten derived from the capsular polysaccharide of a gram-positive bacterium and at least an oligosaccharidic hapten derived from the capsular polysaccharide of a gram-negative bacterium, and wherein said oligosaccharidic haptens are previously activated by introducing terminal esters.
123 citations
Patent•
10 Feb 1993TL;DR: A dual carrier immunogenic construct as mentioned in this paper is composed of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least a secondary carrier comprising a T-dependent antigen conjugated to a primary carrier.
Abstract: A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, treatment, and prevention of diseases.
102 citations
Patent•
27 Jan 1992TL;DR: In this paper, a pneumococcal conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process.
Abstract: A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.
101 citations
TL;DR: The coupling strategy which selectively modified a portion of the sialic acid residues of types II polysaccharide before coupling the polysacchide to TT preserved the epitope essential to protective immunity and enhanced the immunogenicity of the poly Saccharide.
Abstract: This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.
83 citations